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TERLIPRESSIN-RELATED ACUTE MYOCARDIAL INFARCTION:
A CASE REPORT AND LITERATURE REVIEW
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Acute ST-segment elevation myocardial infarction after the administration of terlipressin in patients with
hemorrhagic esophageal varices is a rare but life-threatening complication. We report the case of a 73-
year-old female patient with esophageal variceal bleeding complicated with acute ST-segment elevation
myocardial infarction after intravenous injection of terlipressin. We discuss the underlying mechanisms
of terlipressin-related acute myocardial infarction and review the literature.
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Terlipressin (Glypressin®, Ferring Pharmaceuticals A/S,
Copenhagen, Denmark), a synthetic analog of triglycyl
lysine vasopressin, is effective in controlling hemorrhagic
esophageal varices in patients with liver cirrhosis and
portal hypertension [1–3]. The possible side effects of
terlipressin include abdominal cramping, headache, pallid
face, and arterial blood pressure elevation [2]. However,
less attention has been paid to the use of terlipressin in
patients who are at high risk for cardiovascular events. We
present a rare but crucial case demonstrating persistent
ST-segment elevation myocardial infarction (STEMI) after
a therapeutic dose of terlipressin for esophageal variceal
bleeding. The ST segment returned to baseline after
discontinuation of terlipressin treatment. Unfortunately,
the patient developed cardiogenic shock with multiple
organ failure and expired despite aggressive medical
treatment. The relevant literature was reviewed to explore
the possible pathogenic mechanism.
CASE PRESENTATION
A 73-year-old female with hepatic cirrhosis and esophageal
varices documented for 6 months visited the emergency
department for two episodes of vomiting with fresh blood
and drowsiness during the past 24 hours. She had risk
factors for coronary artery disease, including diabetes and
raised serum cholesterol (256 mg/dL) and triglyceride
levels (302 mg/dL), but no definite prior ischemic cardiac
event. Emergency endoscopy revealed active bleeding
from tortuously protuberant esophageal varices. Initial
management included endoscopic ligation of the esopha-
geal varices, blood transfusion, and saline infusion. Terli-
pressin was administered for active bleeding, as an intra-
venous (IV) bolus of 2 mg injected over 1 minute, followed
by a maintenance dose of 2 mg IV bolus 8 hours later.
The patient was admitted for further management.
Unfortunately, she complained of cold sweating, dyspnea,
and abdominal cramping 4 hours after the second dose of
terlipressin. Physical examination showed blood pressure
of 135/70 mmHg, heart rate of 78 beats/minute, and
respiratory rate of 21 breaths/minute. Moist rales over
bilateral lung fields and S3 gallop over the apex of the heart
were noted. She was intubated immediately for airway
patency owing to impending respiratory failure; 12-lead
surface electrocardiography (ECG) revealed diffuse ST-
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segment elevation up to 4–5 mm in the precordial leads V2
to V5 (Figure 1). Acute STEMI was diagnosed according
to the clinical symptoms and ECG changes. Sublingual
nitroglycerin (0.6 mg) was given to relieve the symptom but
little effect was obtained. Primary percutaneous trans-
luminal coronary angioplasty (PTCA) was considered for
urgent reperfusion of the infarct-related coronary artery
(IRA) within the 12 hours of golden time.
Emergency coronary angiography revealed discrete and
calcified narrowing with 90% luminal diameter stenosis in
the bifurcation of the left anterior descending (LAD) artery-
diagonal 1 (D1) branch without obvious intracoronary
thrombus but thrombolysis in myocardial infarction (TIMI)
grade 2 flow in the LAD artery. No critical stenosis was
found in the left circumflex and right coronary arteries.
Coronary intervention was not performed because of the
preserved coronary blood flow in the IRA (Figure 2). Intra-
aortic balloon counterpulsation was used to augment
perfusion of the coronary vasculature with significant
stenosis in the LAD artery. Persistent ST-segment elevation
with wide QRS complexes (current-of-injury pattern) in
leads V2 to V6, I and aVL on the surface ECG were noted at
the serial follow-up (Figure 3) and did not return to baseline
(Figure 4) until terlipressin (given IV at an interval of 8
hours with a total dose of 14 mg within 48 hours) was
discontinued. Cardiac enzymes were elevated: creatine
phosphokinase (CK) was 812 IU/L and CK-MB was 25.1
IU/L. Cardiac troponin-I was also raised to a peak of 46.36
ng/mL 40 hours after the onset of symptoms. Transthoracic
echocardiography revealed hypokinesia in the anterior and
apicoseptal segments of the left ventricle. Unfortunately,
the patient progressed to cardiogenic shock and multiple
organ failure despite aggressive medical treatment. She
died on the 10th day after coronary care unit admission.
DISCUSSION
Portal hypertensive bleeding is a common and serious
complication of liver cirrhosis. All patients with liver
cirrhosis should undergo endoscopic examination to
evaluate possible causes of current or future portal
hypertensive bleeding [1–3]. In cases of acute esophageal
variceal bleeding, early treatment with vasoactive drugs,
such as terlipressin, somatostatin, or octreotide, can save
lives when skilled endoscopists are not immediately
available [2]. The efficacy and mechanisms of action of
terlipressin in arresting portal hypertensive hemorrhage
and improving the disturbed cardiovascular status of
cirrhotic patients, including those with hepatorenal syn-
drome, are well documented. Due to its vasoconstrictive
effects on dilated splanchnic blood vessels, terlipressin
can reduce blood flow into the portal vein, and thus reduce
portal venous pressure and blood flow through porto-
systemic shunts [2].
Acute myocardial infarction generally occurs in the
presence of known risk factors and pre-existent coronary
artery disease [4]. Atypical presentations due to therapeutic
and illicit drug use are also documented, and lead to the
consideration of alternative pathophysiologic rationales
for myocardial infarction. There are many causes of myo-
cardial infarction without coronary atherosclerosis [4].
These include coronary arteritis; metabolic disease or inti-
mal proliferative disease causing coronary mural thicken-
ing; vasospasm of coronary arteries; dissection of the aorta
involving coronary arteries; infective endocarditis; mural
thrombus from the left atrium, left ventricle, or pulmonary
veins; coronary artery aneurysms; hematologic hyper-
coagulability; cocaine abuse [5,6]; and desmopressin,
which might elicit coronary artery thrombosis in hemo-
philic patients receiving infusions of factor VIII concentrate
[7] or paradoxical coronary vasospasm resulting in acute
myocardial infarction in blood donors [8].
Cardiac events after terlipressin injection are uncom-
mon. To our knowledge, our case is the second report of
terlipressin-related acute myocardial infarction; the first
was reported by Rosario et al in 1996 [9]. They described a
46-year-old cirrhotic patient without previous cardio-
vascular disease who had an episode of sustained ven-
tricular tachycardia (VT) several minutes after injection of
2 mg terlipressin for hemorrhagic esophageal varices.
After the VT ended, surface ECG showed ST-segment
elevation in the precordial leads and echocardiography
revealed hypokinesia over the anteroapical segment of the
left ventricle. Coronary arteriography revealed normal
Figure 1. Marked ST-segment elevation in leads V2 to V5 after injection
of terlipressin. Q waves are also present in leads V2 to V4.
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coronary arteries in the corresponding territories and
relatively normal coronary blood flow, which made the
authors propose that the underlying mechanism of the
terlipressin-associated myocardial infarction was coronary
vasospasm caused by the vasoconstrictive effect of the
drug.
In our case, ST-segment elevation in the precordial
leads accompanied by symptoms of acute coronary
syndrome occurred 12 hours after initiation of terlipressin
treatment. The ST–T change returned to baseline with
pathologic Q waves in leads V1 to V4 after terlipressin was
discontinued. Coronary angiography was performed during
terlipressin treatment. Although there was significant
stenosis in the bifurcation of the LAD-D1 branch, no obvious
thrombus could be demonstrated and TIMI grade 2 flow
in the LAD artery was preserved at emergency coronary
angiography. The time sequence of the events and serial
ECG changes suggested terlipressin as the cause of this
Figure 2. (A) Right coronary angiogram reveals irregular narrowing over the proximal portion of the right coronary artery. (B, C, D) Left coronary
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Figure 3. Prominent ST-segment elevation with tall T waves referred to
as a monophasic “current-of-injury” pattern in leads V2 through V6, I
and aVL 24 hours after the onset of dyspnea.
Figure 4. ST segments return to baseline in the precordial leads and Q
waves in leads V1 to V4.
cardiac event. Therefore, coronary vasoconstriction induced
by terlipressin was considered the most likely mechanism
of inducing severe myocardial damage manifested by the
“current-of-injury” pattern of ECG changes during the
course of terlipressin treatment.
The pathogenesis of terlipressin-related myocardial
ischemia and infarction includes one or more of the following
elements: an increased myocardial oxygen demand in the
face of a limited or fixed supply; marked vasoconstriction of
the coronary arteries; and enhanced platelet aggregation
and thrombus formation. Vasopressin induces an increase
in three major determinants of the myocardial oxygen
demand: heart rate, systemic arterial pressure and left
ventricular contractility [10,11]. In addition to increasing
the myocardial oxygen demand, administration of even
small amounts of vasopressin may cause inappropriate
vasoconstriction of the epicardial coronary arteries, which
may decrease the myocardial oxygen supply and cause
significant ischemic burden. Although vasoconstriction
induced by vasopressin can occur both in normal and
diseased segments of the coronary arteries, the diseased
segments are affected more. Therefore, during vasopressin
treatment, patients with established atherosclerotic coronary
artery disease are probably at higher risk for an ischemic
cardiac event.
In conclusion, intravenous terlipressin is an effective
treatment for patients with esophageal variceal bleeding,
but in rare cases, especially in older patients and those with
risk factors for atherosclerosis, chronic myocardial ische-
mia, and pre-existing coronary artery disease, cardiac com-
plications may ensue. In our case, the patient presented
with chest discomfort, dyspnea, and impending respiratory
failure after terlipressin injection. The clinical symptoms
and ST-segment elevations on surface ECG made physicians
pay more attention to the adverse side effects of terlipressin,
which were considered the most likely cause of the serious
cardiac event.
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